TRIAL DETAIL
Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 02/01/2011 |
Age of Trial (yrs) 13.8 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor + MET/VEGF inhibitor |
|||
Strategy: |
Block KIT + Block related tumor signal paths |
|||
Trial Type: |
GIST not specified. GIST patients known to be enrolled. |
|||
Other Protocol IDs: |
XL184-014 |
|||
Sponsor: |
Exelixis |
|||
Patient Contact: |
Elelixis Clinical Trials 1-800-393-5494
Backup or International 1+650-837-7400 |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics (PK), pharmacodynamics, pharmacogenomic (PGX) and preliminary efficacy following daily oral doses of cabozantinib (XL184) in Japanese patients with advanced or metastatic solid tumors. Also, the effect of XL184 in the treatment of non-small cell lung cancer (NSCLC) patients with various activating mutations will be evaluated at the recommended Phase 2 dose. |
|||
Trial Links |
Trial Results |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
Chuo-ku |
Tokyo |
104-0045 |
Japan |
||
Ariake |
Koto |
135-8550 |
Japan |